WordPress database error: [Can't create table `u102800555_cTMLC`.`wp_icwp_wpsf_ip_meta` (errno: 150 "Foreign key constraint is incorrectly formed")]
CREATE TABLE `wp_icwp_wpsf_ip_meta` ( id int(11) UNSIGNED NOT NULL AUTO_INCREMENT COMMENT 'Primary ID', ip_ref int(11) UNSIGNED NOT NULL COMMENT 'Foreign Key For Primary ID', asn int(10) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ASN', country_iso2 char(2) NOT NULL DEFAULT '' COMMENT 'Country Code ISO 3166-1 alpha-2', pc_is_proxy tinyint(1) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck: Is Proxy?', geo_updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Geolocation data updated at', pc_last_check_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck last lookup at', updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Last Updated', created_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Created', deleted_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Soft Deleted', PRIMARY KEY (id), FOREIGN KEY (ip_ref) REFERENCES wp_icwp_wpsf_ips(id) ON DELETE CASCADE ON UPDATE CASCADE ) DEFAULT CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_520_ci;

WordPress database error: [Can't create table `u102800555_cTMLC`.`wp_icwp_wpsf_ip_meta` (errno: 150 "Foreign key constraint is incorrectly formed")]
CREATE TABLE `wp_icwp_wpsf_ip_meta` ( id int(11) UNSIGNED NOT NULL AUTO_INCREMENT COMMENT 'Primary ID', ip_ref int(11) UNSIGNED NOT NULL COMMENT 'Foreign Key For Primary ID', asn int(10) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ASN', country_iso2 char(2) NOT NULL DEFAULT '' COMMENT 'Country Code ISO 3166-1 alpha-2', pc_is_proxy tinyint(1) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck: Is Proxy?', geo_updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Geolocation data updated at', pc_last_check_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'ProxyCheck last lookup at', updated_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Last Updated', created_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Created', deleted_at int(15) UNSIGNED NOT NULL DEFAULT 0 COMMENT 'Soft Deleted', PRIMARY KEY (id), FOREIGN KEY (ip_ref) REFERENCES wp_icwp_wpsf_ips(id) ON DELETE CASCADE ON UPDATE CASCADE ) DEFAULT CHARACTER SET utf8mb4 COLLATE utf8mb4_unicode_520_ci;

ZURA Stock Alert: Low-Float Zura Bio Rockets 300% - Stock Market Latest

One of today’s biggest market sensations is Zura Bio Limited (NASDAQ:ZURA). The clinical-stage biotechnology firm recently completed a merger with JATT Acquisition Corp, a special-purpose acquisition company (SPAC). Following a successful shareholder vote on March 16, ZURA stock began trading on the Nasdaq yesterday.

The newly formed company made its trading debut on Tuesday, March 21, and closed the day down 11%. Since then, however, it has truly skyrocketed, rising more than 300% despite multiple trading halts being imposed by the Nasdaq. However, the stock also boasts a surprisingly low float of roughly 5 million shares, causing some investors to eye it with skepticism.

What’s Happening With ZURA Stock

It’s not unusual for a newly merged deSPAC to enjoy impressive gains after its initial public offering (IPO). Additionally, companies that go public through a SPAC merger can sometimes have a low float percentage. Today, speculative investors have been closely watching ZURA stock as it shoots up. However, some have expressed concern regarding a shareholder disclosure. Per the company’s 8K filing:

“As a result of a a share distribution by Hana Immunotherapeutics LLC (“Hana”), Hana will own 5,404,274 Class A Shares of the post-combination company. Willow Gate LLC (“Willow”) will own 2,702,623 Class A Shares and Stone Peach Properties LLC (“Stone Peach”) will own 2,701,543 Class A Shares. The shares held by Willow and Stone Peach will not be subject to the lock-up restrictions.”

As two key investors are not facing a lock-up period, they have nothing stopping them from offloading their ZURA stock holdings. Were they to start selling, the stock would fall, but it would also lead to a higher float percentage.

This shouldn’t necessarily be seen as an indication of how ZURA stock will perform in the long term. Seeking Alpha reports that Zura is currently undergoing clinical testing for two drug candidates that treat disorders, including alopecia areata, diabetes, and asthma. The current “biotech gold rush” means there will be plenty of opportunities for new companies in the space.

On the date of publication, Samuel O’Brient did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Samuel O’Brient has been covering financial markets and analyzing economic policy for three-plus years. His areas of expertise involve electric vehicle (EV) stocks, green energy and NFTs. O’Brient loves helping everyone understand the complexities of economics. He is ranked in the top 15% of stock pickers on TipRanks.

Source link

Share with your friends!

Products You May Like

Leave a comment

Your email address will not be published. Required fields are marked *

Get the latest stocks updates
straight to your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.